A BILL 
To amend section 505(j) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 355(j)) with respect to a proc-
ess to inform persons submitting an abbreviated applica-
tion for a new drug whether the new drug is qualitatively 
or quantitatively the same as a listed drug, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Increasing Trans-
4
parency in Generic Drug Applications Act of 2022’’. 
5
05:28 Apr 07, 2022
H7032
2 
•HR 7032 IH
SEC. 2. DETERMINING WHETHER PROPOSED NEW GENERIC 
1
DRUGS 
ARE 
QUALITATIVELY 
OR 
QUAN-
2
TITATIVELY THE SAME AS THE LISTED DRUG. 
3
(a) IN GENERAL.—Section 505(j)(3) of the Federal 
4
Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(3)) is 
5
amended by adding at the end the following: 
6
‘‘(H)(i) Upon request (in controlled correspondence 
7
or otherwise) by a person that has submitted or intends 
8
to submit an abbreviated application for a new drug under 
9
this subsection or on the Secretary’s own initiative during 
10
the review of such abbreviated application, the Secretary 
11
shall inform the person whether such new drug is quali-
12
tatively and quantitatively the same as the listed drug. 
13
‘‘(ii) If the Secretary determines that such new drug 
14
is not qualitatively or quantitatively the same as the listed 
15
drug, the Secretary shall identify and disclose to the per-
16
son— 
17
‘‘(I) the ingredient or ingredients that cause the 
18
new drug not to be qualitatively or quantitatively the 
19
same as the listed drug; and 
20
‘‘(II) the quantity or proportion of any ingre-
21
dient in the listed drug for which there is an identi-
22
fied quantitative deviation. 
23
‘‘(iii) If the Secretary determines that such new drug 
24
is qualitatively and quantitatively the same as the listed 
25
drug, the Secretary shall not change or rescind such deter-
26
05:28 Apr 07, 2022
H7032
3 
•HR 7032 IH
mination after the submission of an abbreviated applica-
1
tion for such new drug under this subsection unless— 
2
‘‘(I) the formulation of the listed drug has been 
3
changed and the Secretary has determined that the 
4
prior listed drug formulation was withdrawn for rea-
5
sons of safety or effectiveness; or 
6
‘‘(II) the Secretary makes a written determina-
7
tion that the prior determination must be changed 
8
because an error has been identified. 
9
‘‘(iv) If the Secretary makes a written determination 
10
described in clause (iii)(II), the Secretary shall provide no-
11
tice and a copy of the written determination to the person 
12
making the request under clause (i). 
13
‘‘(v) The disclosures required by this subparagraph 
14
are disclosures authorized by law under section 1905 of 
15
title 18, United States Code.’’. 
16
(b) GUIDANCE.— 
17
(1) IN
GENERAL.—Not later than one year 
18
after the date of enactment of this Act, the Sec-
19
retary of Health and Human Services shall issue 
20
guidance describing how the Secretary will deter-
21
mine whether a new drug is qualitatively and quan-
22
titatively the same as the listed drug (as such terms 
23
are used in section 505(j)(3)(H) of the Federal 
24
Food, Drug, and Cosmetic Act, as added by sub-
25
05:28 Apr 07, 2022
H7032
4 
•HR 7032 IH
section (a)), including with respect to assessing pH 
1
adjusters. 
2
(2) PROCESS.—In issuing guidance as required 
3
by paragraph (1), the Secretary of Health and 
4
Human Services shall— 
5
(A) publish draft guidance; 
6
(B) provide a period of at least 60 days for 
7
comment on the draft guidance; and 
8
(C) after considering any comments re-
9
ceived, publish final guidance. 
10
(c) APPLICABILITY.—Section 505(j)(3)(H) of the 
11
Federal Food, Drug, and Cosmetic Act, as added by sub-
12
section (a), applies beginning on the date of enactment 
13
of this Act, irrespective of the date on which the guidance 
14
required by subsection (b) is finalized. 
15
Æ 
05:28 Apr 07, 2022
H7032
